REVB logo

REVELATION BIOSCIENCES INC

REVBNASDAQ
πŸ† #5190 by market capEarnings Nov 4US Equity
$3.72β–Ό $0.01 (βˆ’0.27%)
πŸŒ™ After hours$3.69β–Ό 0.81%Regular close Β· extended-hours price shown
πŸ””
Track REVB
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.3%
7dβ–Ό 0.5%
14dβ–Ό 30.1%
30dβ–Ό 35.2%
ytdβ–Ό 83.3%
1yβ–Ό 89.8%
🏦Market Cap
$2M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$3.55 – $3.84
52-Week Range
$3.08 – $40.60
Volume (shares)
9,021
Avg Volume (shares)
β€”
Shares Outstanding
569,058
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-0.1
P/S Ratio
0.0x
EPS (TTM)
$-19.65
Dividend Yield
0.00%
Dilution (1yr)
+79.2%
REVB logo

REVELATION BIOSCIENCES INC

REVB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$9Mβ–² +13.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$8Mβ–Ό βˆ’54.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
89Kβ–² +79.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$10Mβ–² +$3M YoY
StockOtter Β· stockotter.space

About REVELATION BIOSCIENCES INC

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

GuruFocusΒ·12d ago

Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

[url="]Revelation Biosciences, Inc.[/url] (NASDAQ: REVB) (the Γ’Β€ΒœCompanyҀ or Γ’Β€ΒœRevelationҀ), a clinical-stage life sciences company developing innovative s

Business WireΒ·Aug 19

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the β€œCompany” or β€œRevelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic di

AccesswireΒ·Aug 6

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chr

AccesswireΒ·Aug 3

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chr